Association between rectal bleeding and the absolute dose volume of the rectum following image‑guided radiotherapy for patients with prostate cancer

Kotabe,Kazuki; Nakayama,Hidetsugu; Takashi,Aruga; Takahashi,Atsuko; Tajima,Tsuyoshi; Kume,Haruki

doi:10.3892/ol.2018.8888

Association between rectal bleeding and the absolute dose volume of the rectum following image‑guided radiotherapy for patients with prostate cancer

Authors:
- Kazuki Kotabe
- Hidetsugu Nakayama
- Aruga Takashi
- Atsuko Takahashi
- Tsuyoshi Tajima
- Haruki Kume
View Affiliations

Affiliations: Department of Radiation Oncology, National Center for Global Health and Medicine, Tokyo 162‑8655, Japan, Department of Radiation Oncology, Funabashi Municipal Medical Center, Tokyo 162‑8655, Japan, Department of Urology, National Center for Global Health and Medicine, Tokyo 162‑8655, Japan, Department of Radiology, National Center for Global Health and Medicine, Tokyo 162‑8655, Japan
Published online on: June 4, 2018 https://doi.org/10.3892/ol.2018.8888
Pages: 2741-2749

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The association between rectal bleeding and the received dose relative to the volume of the rectum is well established in prostate cancer patients who have undergone radiotherapy. The relative volume of the rectum is affected by the rectal anatomical volume, which depends on the definition of rectal length. Compared with the relative rectal volume, the absolute volume of the rectum may be more associated with rectal bleeding. The present study investigated the absolute volume of the rectum that may be used to predict late rectal bleeding following intensity‑modulated radiotherapy (IMRT) and image‑guided radiotherapy (IGRT). The cases of 82 patients of prostate cancer, who underwent IMRT and IGRT, were retrospectively evaluated by evaluating dose volume histograms. The median patient age was 73.4 years (range, 51.3‑85.9 years). The median total prescribed dose was 76 Gy given in 38 fractions. The absolute and relative dose volumes of the rectum were evaluated by multivariate analysis, and the optimal dose to prevent rectal bleeding was determined. The actuarial ≥grade 1 rectal bleeding rate at 4 years was 4.5% (95% confidence interval, 1.5‑13.4%) with a median observation period of 45.3 months. The absolute rectal volume (ml) treated with 60 Gy was the only significant risk factor for rectal bleeding (P<0.05), but the relative rectal volume (%) was not identified as a significant factor by the multivariate analysis. When the rectal volume of 5 or 10 ml received 60 Gy (D5cc and D10cc), rectal bleeding was expected to occur in 3.3 and 7.3% of the patients, respectively. Rectal D5cc ≤60 Gy is recommended to prevent late ≥grade 1 rectal bleeding in IGRT.

View Figures

View References

1	Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, et al: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 375:1415–1424. 2016. View Article : Google Scholar : PubMed/NCBI
2	Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK and Pollack A: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 70:67–74. 2008. View Article : Google Scholar
3	Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA and Shipley WU: Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 294:1233–1239. 2005. View Article : Google Scholar : PubMed/NCBI
4	Beckendorf V, Guérif S, Le Prisé E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, et al: The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity. Int J Radiat Oncol Biol Phys. 60:1056–1065. 2004. View Article : Google Scholar : PubMed/NCBI
5	Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, et al: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8:475–487. 2007. View Article : Google Scholar : PubMed/NCBI
6	Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L and Lebesque JV: Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 24:1990–1996. 2006. View Article : Google Scholar : PubMed/NCBI
7	Viani GA, Stefano EJ and Afonso SL: Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 74:1405–1418. 2009. View Article : Google Scholar : PubMed/NCBI
8	Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, Gadd J, Warrington A, Bidmead M and Horwich A: Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 92:488–498. 2005. View Article : Google Scholar : PubMed/NCBI
9	Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B and Zelefsky MJ: Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 85:686–692. 2013. View Article : Google Scholar : PubMed/NCBI
10	Fonteyne V, Sadeghi S, Ost P, Vanpachtenbeke F, Vuye P, Lumen N and de Meerleer G: Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience. Acta Oncol. 54:854–861. 2015. View Article : Google Scholar : PubMed/NCBI
11	Davis KM, Kelly SP, Luta G, Tomko C, Miller AB and Taylor KL: The association of long-term treatment-related side effects with cancer-specific and general quality of life among prostate cancer survivors. Urology. 84:300–306. 2014. View Article : Google Scholar : PubMed/NCBI
12	Delobel JB, Gnep K, Ospina JD, Beckendorf V, Chira C, Zhu J, Bossi A, Messai T, Acosta O, Castelli J and de Crevoisier R: Nomogram to predict rectal toxicity following prostate cancer radiotherapy. PLoS One. 12:e01798452017. View Article : Google Scholar : PubMed/NCBI
13	Fonteyne V, Ost P, Vanpachtenbeke F, Colman R, Sadeghi S, Villeirs G, Decaestecker K and de Meerleer G: Rectal toxicity after intensity modulated radiotherapy for prostate cancer: Which rectal dose volume constraints should we use? Radiother Oncol. 113:398–403. 2014. View Article : Google Scholar : PubMed/NCBI
14	Fellin G, Rancati T, Fiorino C, Vavassori V, Antognoni P, Baccolini M, Bianchi C, Cagna E, Borca VC, Girelli G, et al: Long term rectal function after high-dose prostatecancer radiotherapy: Results from a prospective cohort study. Radiother Oncol. 110:272–277. 2014. View Article : Google Scholar : PubMed/NCBI
15	Pearlstein KA and Chen RC: Comparing dosimetric, morbidity, quality of life and cancer control outcomes after 3D conformal, intensity-modulated and proton radiation therapy for prostate cancer. Semin Radiat Oncol. 23:182–190. 2013. View Article : Google Scholar : PubMed/NCBI
16	Valdagni R, Kattan MW, Rancati T, Yu C, Vavassori V, Fellin G, Cagna E, Gabriele P, Mauro FA, Baccolini M, et al: Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys. 82:1957–1966. 2012. View Article : Google Scholar : PubMed/NCBI
17	Pederson AW, Fricano J, Correa D, Pelizzari CA and Liauw SL: Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: An exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity. Int J Radiat Oncol Biol Phys. 82:235–241. 2012. View Article : Google Scholar : PubMed/NCBI
18	Swanson GP and Stathakis S: Rectal dose constraints for intensity modulated radiation therapy of the prostate. Am J Clin Oncol. 34:188–195. 2011.PubMed/NCBI
19	Michalski JM, Gay H, Jackson A, Tucker SL and Deasy JO: Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys. 76(3 Suppl): S123–S129. 2010. View Article : Google Scholar : PubMed/NCBI
20	Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H, Evans PM, Gianolini S, Mayles WP, Moore AR, et al: Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: Evidence from MRC RT01 trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys. 76:747–754. 2010. View Article : Google Scholar : PubMed/NCBI
21	D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:969–974. 1998. View Article : Google Scholar : PubMed/NCBI
22	Fowler JF: The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 62:679–694. 1989. View Article : Google Scholar : PubMed/NCBI
23	U.S. Department of Health and Human Services, National Institutes of Health and National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfJune 14–2010
24	Kupelian PA, Reddy CA, Carlson TP and Willoughby TR: Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: Absolute or relative rectal volume? Cancer J. 8:62–66. 2002. View Article : Google Scholar : PubMed/NCBI
25	Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, Carver B, Coleman J, Lovelock M and Hunt M: Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 84:125–129. 2012. View Article : Google Scholar : PubMed/NCBI
26	Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M, Parliament MB, Pollack A, Markoe AM, Harms W, et al: Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 56:192–198. 2003. View Article : Google Scholar : PubMed/NCBI
27	Guckenberger M, Ok S, Polat B, Sweeney RA and Flentje M: Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer. Strahlenther Onkol. 186:535–543. 2010. View Article : Google Scholar : PubMed/NCBI
28	Ghadjar P, Vock J, Vetterli D, Manser P, Bigler R, Tille J, Madlung A, Behrensmeier F, Mini R and Aebersold DM: Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. Radiat Oncol. 3:352008. View Article : Google Scholar : PubMed/NCBI
29	Lips IM, Dehnad H, van Gils CH, Boeken Kruger AE, van der Heide UA and van Vulpen M: High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: Acute and late toxicity in 331 patients. Radiat Oncol. 3:152008. View Article : Google Scholar : PubMed/NCBI
30	Chan LW, Xia P, Gottschalk AR, Akazawa M, Scala M, Pickett B, Hsu IC, Speight J and Roach M III: Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 72:69–77. 2008. View Article : Google Scholar : PubMed/NCBI
31	Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, et al: Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 62:1297–1308. 2005. View Article : Google Scholar : PubMed/NCBI
32	Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I and Kuban DA: Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 54:1314–1321. 2002. View Article : Google Scholar : PubMed/NCBI
33	Koper PC, Heemsbergen WD, Hoogeman MS, Jansen PP, Hart GA, Wijnmaalen AJ, van Os M, Boersma LJ, Lebesque JV and Levendag P: Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 58:1072–1082. 2004. View Article : Google Scholar : PubMed/NCBI
34	Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca VC, Girelli G, Mapelli M, Menegotti L, Nava S and Valdagni R: Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: Preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys. 70:1130–1137. 2008. View Article : Google Scholar : PubMed/NCBI
35	de Crevoisier R, Tucker SL, Dong L, Mohan R, Cheung R, Cox JD and Kuban DA: Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 62:965–973. 2005. View Article : Google Scholar : PubMed/NCBI
36	Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D and Pollack A: Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 62:397–405. 2005. View Article : Google Scholar : PubMed/NCBI